After years of scientific training in academic and industry labs, I have started my own consulting firm to address a critical need among small US biotech firms. Due to decreased VC funding and a shift by Big Pharma towards funding late-stage products, many US biotech products were abandoned that hold great clinical and commercial promise. I have joined with a team of other like-minded consultants to create cost-effective commercialization solutions for viable yet abandoned products.
The key differentiator of our commercialization solutions lies in an understanding that the paradigm by which biopharma products reach the market has fundamentally changed. Many Asia-Pacific markets are growing in importance on the global scene, while the US and European markets have stagnated. Developing commercialization solutions to meet the needs of the healthcare market in the Asia-Pacific region can be more cost effective and may benefit a larger population.